StockData
NovoCure Ltd logo

NovoCure Ltd (NVCR) stock

NVCRNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 9/3032% below fair value
$10.71+0.02 (+0.19%)

Close on Nov 20, 2026Market cap $1.25BP/E –Yield –

NovoCure free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

NovoCure's free cash flow for the twelve months ending Sep 30, 2026 was -$24.61M. For fiscal 2025 it was -$75.68M. The highest annual figure on record is $84.18M in fiscal 2020.

Annual free cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$75.68M–
FY2024Dec 31, 2024-$69.22M–
FY2023Dec 31, 2023-$100.43M-1165.0%
FY2022Dec 31, 2022$9.43M-83.9%
FY2021Dec 31, 2021$58.59M-30.4%
FY2020Dec 31, 2020$84.18M+421.7%
FY2019Dec 31, 2019$16.14M–
FY2018Dec 31, 2018-$8.58M–
FY2017Dec 31, 2017-$40.50M–
FY2016Dec 31, 2016-$113.27M–
FY2015Dec 31, 2015-$104.55M–
FY2014Dec 31, 2014-$75.09M–
FY2013Dec 31, 2013-$54.92M–

Quarterly free cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026$15.75M+5.5%
Q2 FY2026Jun 30, 2026$1.22M–
Q1 FY2026Mar 31, 2026-$18.67M–
Q4 FY2025Dec 31, 2025-$22.90M–
Q3 FY2025Sep 30, 2025$14.92M–
Q2 FY2025Jun 30, 2025-$21.42M–
Q1 FY2025Mar 31, 2025-$46.28M–
Q4 FY2024Dec 31, 2024-$12.39M–
Q3 FY2024Sep 30, 2024-$307.00K–
Q2 FY2024Jun 30, 2024-$13.17M–
Q1 FY2024Mar 31, 2024-$43.36M–
Q4 FY2023Dec 31, 2023-$21.38M–
Q3 FY2023Sep 30, 2023-$26.57M-258.9%
Q2 FY2023Jun 30, 2023-$29.67M-355.1%
Q1 FY2023Mar 31, 2023-$22.82M–
Q4 FY2022Dec 31, 2022-$10.14M-7898.5%
Q3 FY2022Sep 30, 2022$16.72M-20.8%
Q2 FY2022Jun 30, 2022$11.63M-50.6%
Q1 FY2022Mar 31, 2022-$8.78M-163.6%
Q4 FY2021Dec 31, 2021$130.00K-99.7%
Q3 FY2021Sep 30, 2021$21.10M-25.1%
Q2 FY2021Jun 30, 2021$23.55M+149.9%
Q1 FY2021Mar 31, 2021$13.80M–
Q4 FY2020Dec 31, 2020$47.72M+1121.4%
Q3 FY2020Sep 30, 2020$28.19M+131.1%
Q2 FY2020Jun 30, 2020$9.43M+41.3%
Q1 FY2020Mar 31, 2020-$1.16M–
Q4 FY2019Dec 31, 2019$3.91M-74.0%
Q3 FY2019Sep 30, 2019$12.20M+184.7%
Q2 FY2019Jun 30, 2019$6.67M–
Q1 FY2019Mar 31, 2019-$6.64M–
Q4 FY2018Dec 31, 2018$15.02M–
Q3 FY2018Sep 30, 2018$4.29M+113.9%
Q2 FY2018Jun 30, 2018-$8.35M–
Q1 FY2018Mar 31, 2018-$17.56M–
Q4 FY2017Dec 31, 2017-$8.31M–
Q3 FY2017Sep 30, 2017$2.00M–
Q2 FY2017Jun 30, 2017-$6.25M–
Q1 FY2017Mar 31, 2017-$27.94M–
Q4 FY2016Dec 31, 2016-$14.34M–

More NovoCure figures

See a number that looks wrong?